Edesa Biotech, Inc.
EDSAHealthcare|Biotechnology|CA
$2.14
+0.01 (+0.47%)
DCF Value
$2.00
Tangible Book / Share
$0.77
Cash / Share
$1.15
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07889492 A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo | Non-Segmental Vitiligo (NSV) | P2 | Recruiting | 80 | RCT, Double-blind | EB06 |
| NCT06701656 JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab | Acute Respiratory Distress Syndrome (ARDS), ARDS | P2 | Recruiting | 200 | RCT, Double-blind | Cohort C: bevacizumab, Cohort C: placebo |
| NCT06701682 JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab | Acute Respiratory Distress Syndrome (ARDS), ARDS | P2 | Recruiting | 200 | RCT, Double-blind | Cohort A: vilobelimab, Cohort A: placebo |
| NCT06703073 JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) | Acute Respiratory Distress Syndrome (ARDS), ARDS | P2 | Recruiting | 600 | RCT, Double-blind | Cohort A: vilobelimab, Cohort A: placebo, Cohort B: paridiprubart, Cohort B: placebo, Cohort C: bevacizumab, Cohort C: placebo |
| NCT06701669 JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart | Acute Respiratory Distress Syndrome (ARDS), ARDS | P2 | Recruiting | 200 | RCT, Double-blind | Cohort B: paridiprubart, Cohort B: placebo |
| NCT04401475 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19 | COVID-19, ARDS | P2P3 | Terminated | 278 | RCT, Double-blind | SOC plus 15mg/kg EB05 IV |
| NCT03680131 Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis | Allergic Contact Dermatitis | P2 | Completed | 211 | RCT, Double-blind | EB01 Cream Placebo, EB01 Cream 0.2%, EB01 Cream 1.0%, EB01 Cream 2.0% |